Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Ian Bruce, Mohammed Akhlaq, Graham C Bloomfield, Emma Budd, Brian Cox, Bernard Cuenoud, Peter Finan, Peter Gedeck, Julia Hatto, Judy F Hayler, Denise Head, Thomas Keller, Louise Kirman, Catherine Leblanc, Darren Le Grand, Clive McCarthy, Desmond O'Connor, Charles Owen, Mrinalini S Oza, Gaynor Pilgrim, Nicola E Press, Lilya Sviridenko, Lewis Whitehead
Index: Bioorg. Med. Chem. Lett. 22(17) , 5445-50, (2012)
Full Text: HTML
Abstract
Using a parallel synthesis approach to target a non-conserved region of the PI3K catalytic domain a pan-PI3K inhibitor 1 was elaborated to provide alpha, delta and gamma isoform selective Class I PI3K inhibitors 21, 24, 26 and 27. The compounds had good cellular activity and were selective against protein kinases and other members of the PI3K superfamily including mTOR and DNA-PK.Copyright © 2012 Elsevier Ltd. All rights reserved.
Related Compounds
Related Articles:
2008-11-13
[J. Med. Chem. 51 , 6740-51, (2008)]
Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase.
2008-06-01
[Bioorg. Med. Chem. 16 , 6193-206, (2008)]
2015-04-01
[Neurourol. Urodyn. 34(4) , 368-74, (2015)]
Multicomponent assembly of proposed DNA precursors in water.
2012-08-22
[J. Am. Chem. Soc. 134(33) , 13889-95, (2012)]
2013-03-01
[ChemMedChem 8(3) , 484-96, (2013)]